Page 16 - Aurobindo Pharma
USFDA move not to hurt growth, new product nods to be delayed: Aurobindo
The company's stock took a beating after the USFDA pointed out data integrity lapses at the firm's formulations facility in Telangana's Bachupally
 "USFDA move not to hurt growth, new product nods to be delayed: Aurobindo")
Aurobindo Pharma confident of growth despite regulatory action, drug recall
The company said it was confident that the contamination in valsartan will not spread to other products
 "Aurobindo Pharma confident of growth despite regulatory action, drug recall")
Aurobindo Pharma gets 10 observations from USFDA for Unit 3 in Hyderabad
None of the observations are repetitive and are more procedural in nature, Aurobindo Pharma said
 "Aurobindo Pharma gets 10 observations from USFDA for Unit 3 in Hyderabad")
Growth across geographies keeps analysts positive on Aurobindo Pharma
Product launches, acquisitions are expected to drive US, EU prospects
 "Growth across geographies keeps analysts positive on Aurobindo Pharma")
FDA designates Aurobindo's 3 facilities as 'Official Action Indicated'
According to FDA's definitions, Official Action Indicated means "objectionable conditions were found and regulatory and/or administrative sanctions by FDA are indicated" during inspections
Aurobindo's strong European, US prospects keeping analysts bullish
As the pricing pressure in US generics market recedes, the company is also expected to fair well, say analysts, who see growth impetus coming from its recent acquisitions in the US and Europe
Aurobindo Pharma acquires 7 oncology products from US company for $300 mn
The product portfolio is expected to generate a revenue of around $100 million for first 12 months after completion of the transaction for Aurobindo
 "Aurobindo Pharma acquires 7 oncology products from US company for $300 mn")
Lacunae in Aurobindo Pharma's Medak facility in Andhra, says FDA report
Besides, the report said preparative apparel was not worn as necessary to protect drug products from contamination
 "Lacunae in Aurobindo Pharma's Medak facility in Andhra, says FDA report")
Aurobindo acquires Apotex Inc's biz in 5 European countries for 74 mn euros
BS ReporterHyderabad, 14 July: Aurobindo Pharma Limited announced today that its step-down subsidiary Agile Pharma B V(Netherlands ) signed a definitive agreement to acquire from Canadian pharmaceuticals company Apotex International Inc. its commercial operations and certain supporting infrastructure in five European countries for Euro 74 million(Rs 5.93 billion) in an all cash deal. The company expects to close the transaction in 3-6 months.The acquisition is in line with Aurobindo's strategy to strengthen and grow its European business and to expand in Eastern Europe, the company said.The acquisition includes a portfolio of over 200 prescription drugs and 88 OTC products and an additional pipeline of over 20 products which are expected to be launched over the next two years, besides a manufacturing facility in Leiden the Netherlands, with capabilities across manufacturing and packaging and capacity of 1.8 billion tablets per annum.With the acquisition of Apotex Inc's commercial ...
Aurobindo Pharma: US sales, European biz suggest drivers are in place
The acquired business is estimated to have annual sales of euro 130 million, according to analysts, and will add to Aurobindo's prospects in Europe
Aurobindo acquires Apotex's commercial operations in 5 European countries
Aurobindo Pharma had inked a binding agreement on July 14, 2018, to acquire five of Apotex' European businesses
Aurobindo Pharma's Q3 profit surges 19.69% to Rs 712 crore on robust sales
Revenues from operations increased 21.5 percent to 5,269.7 crore during the quarter under review as compared to Rs 4336.1 crore in the year ago period
Aurobindo Pharma's Q3 profit surges 19.69% to Rs 712 crore on robust sales
'We have delivered a robust revenue growth of 22%', said Aurobindo Pharma MD N Govindarajan
Aurobindo Pharma to acquire oncology products from US-based firm in $300 mn
Acrotech will be acquiring the product portfolio on a debt free and cash free basis, Aurobindo Pharma Ltd said in a regulatory filing
Aurobindo expects Sandoz buy to make it second-largest generics firm in US
The Hyderabad-based company is at fifth place in prescription sales, next to Indian counterpart Lupin, in the US
 "Aurobindo expects Sandoz buy to make it second-largest generics firm in US")
Aurobindo Pharma USA recalls 80 lots of blood pressure drug from US
To date, Aurobindo Pharma USA Inc has not received any reports of adverse events related to this recall, the company said
 "Aurobindo Pharma USA recalls 80 lots of blood pressure drug from US")
Aurobindo's injectable business grows 8% year-on-year to $50 mn in Q2
Analysts feel R&D costs are set to rise as a result of injectables and biosimilars focus
Aurobindo Pharma gets final approval from USFDA to market anaesthesia drug
The approved product is a generic equivalent of Organon's Norcuron Injection
Aurobindo Pharma gets USFDA nod to market potassium chloride pills in US
The potassium chloride tablets are for treating hypokalemia, a condition wherein there is a drop in the potassium-level in the blood
Aurobindo Pharma arm inks pact with Shandong Luoxin to form JV in China
The JV will also undertake contract manufacturing for non-nebuliser inhaler products